Fig. 1: Antibody levels following BNT162b mRNA Covid19 vaccine after a median of 22 and 100 days after the second dose in patients with CLL. | Leukemia

Fig. 1: Antibody levels following BNT162b mRNA Covid19 vaccine after a median of 22 and 100 days after the second dose in patients with CLL.

From: Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia

Fig. 1

a Time course following BNT162b mRNA Covid19 vaccine, each dot represents immune response level for the whole cohort. b Time course following BNT162b mRNA Covid19 vaccine, each dot represents immune response level only for patients with CLL who were tested positive in the first serology test. c Arrow diagram presenting the dynamics of antibody value along 100 days of follow-up.

Back to article page